Stocks cut gains, despite oil rebound, after Gilead trial disappoints

FORBES | In yet another volatile session on Thursday, stocks pared back gains despite a rebound in oil prices, after reports that a Gilead Sciences clinical trial for its remdesivir drug was not effective in treating coronavirus—though the company quickly disputed that it was an inconclusive trial. Stocks rose earlier in the day, with the Dow up to 400 points higher, thanks to a rebound in oil prices: WTI crude oil futures have stabilized since their unprecedented drop earlier this week, rising over 40% in the last two days alone.

To read the full article, click here.

  • LinkedIn
  • Twitter

© 2020 Energen. This website represents a proof of concept of the future platform